FDA and EMA Grant Orphan Drug Designation to Mocravimod for the Treatment of Acute Myeloid Leukemia (AML) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Priothera announced that the US FDA and the European Medicines Agency had both granted orphan drug designation to mocravimod for the treatment of AML in patients undergoing allogeneic HSCT.